Morgan Stanley (MS)
NYSEFinancialsFinancial - Capital MarketsSnapshot 2026-10-30
$184.30-3.00%
Close 2026-10-30 · 1-day change
NYSEFinancialsFinancial - Capital MarketsSnapshot 2026-10-30
Research Workspace
Put MS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Investment Banking & Brokerage is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Net revenues reach about $70.6 billion: Revenue: $33.28B.
View ThesisRevenue is growing steadily — about 9% over the past year.
View GrowthRanks in the weakest quality tier of its industry — roughly the bottom 23%, softest on free-cash-flow margins.
View QualityManagement screens strong on capital allocation, earnings delivery.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskMorgan Stanley’s investment-banking and wealth-management growth supports the case, but revenue growth has slowed. Revenue grew 12% year over year in Q3 FY2026, after 27% in Q2; Q3 earnings beat. MS trades at 15× P/E versus a 17× peer median, and its own history of 17×. The desk says expectations look modest versus its growth view. Fragile cash backing weakens reported profits, and the model puts next-quarter miss probability at 16%. The 15× multiple must be earned against peers; peer multiples imply a price roughly in line with where it trades (about fair). This read is provisional; the thesis is on watch.
Trailing returns as of 2026-10-30. MS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 26 analysts currently covering MS (as of Oct 2026).
Based on 4 Wall Street analysts offering 12-month price targets for MS in the last 4 months.
Continue this research
Compare MS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| MS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Investment Banking & Brokerage — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put MS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $184.30
The last 12 months of price, then the range of analyst 12-month targets from today’s $184.30.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Appeals court revived financial elder-abuse claims, creating legal and reputational risk.
Advances: Deliver strong quarterly earnings performance
Reported competition for Anthropic’s IPO mandate could support investment-banking revenue.
Morgan Stanley officially joined a major financing structure, supporting advisory and financing activity.
Morgan Stanley unit acquisition expands its services platform, modestly supporting growth.
UK savings-market entry via Raisin expands Morgan Stanley's business, though thesis impact appears incremental.
Advances: Deliver strong quarterly earnings performance
Earnings beat supports strong performance, though the reported trading-mix concern tempers the positive.
Strong earnings performance supports growth objectives.
Advances: Deliver strong quarterly earnings performance
Earnings analysis highlights catalysts for growth.
